Heiko Spallek

Professor Heiko Spallek serves as Academic Lead Digital Health and Health Service Infomatics of The University of Sydney. In 1993, Professor Spallek graduated from the School of Dentistry, Humboldt University Berlin where he continued his career and was appointed in the Department of Periodontology and also received his PhD in the field of dental material sciences. While at Temple University School of Dentistry, Philadelphia, he earned an MSBA with a concentration in Computer and Information Science from the Fox School of Business and Management at Temple in 2000.



Jeremy Hammond

Dr Jeremy Hammond is the Director, Strategic Ventures at the University of Sydney, where he leads university-wide transformation initiatives. He is a linguist by trade, with a PhD from the Max Planck Institute for Psycholinguistics specialising in field experiments on indigenous languages in Southern Vanuatu and has experience in developing capabilities in high performance computing, informatics, and data services. These days, both his coding and Austronesian languages are rusty with his focus now on transforming the University for the next generation of researchers and students.



Michael Winlo

Dr. Michael Winlo has served as the CEO at Linear Clinical Research since April 2016. In that time, WA’s only dedicated early phase clinical research unit has grown significantly with clientele including innovative biotech start-ups and multinational pharmaceutical companies from the USA, Europe, Japan and China. Linear was the first site in Australia to successfully launch electronic source capture and earned a national Business Services Award in 2017. Prior to Linear, Michael was based in Silicon Valley as the health lead for Palantir Technologies - one of the largest privately held big data companies in the world. There, Michael led deployments for some of the largest health companies and government organisations in the US and UK. Michael holds an Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Western Australia as well as an MBA from Stanford University Graduate School of Business where he also completed the Stanford Biodesign Cours.



Gordon McGurk

Dr Gordon McGurk is currently the chair of the Royal Brisbane and Women’s Hospital Human Research Ethics Committee, and Director of OmniAdvisory Consulting. His background is in science, public policy development, and corporate governance having spent 15 years in the Commonwealth Public Service.

He holds a Doctor of Philosophy (PhD) in Genetics from the University of Edinburgh and is in the final year of a Juris Doctor through the University of Southern Queensland. He is also completing the qualifications for a Post-Graduate Diploma in Corporate Governance through the Governance Institute of Australia. He is also a Graduate of the Australian Institute of Company Directors.



Professor Lisa Askie

Professor Askie leads a team at the NHMRC Clinical Trials Centre, University of Sydney, which manages the Australian New Zealand Clinical Trials Registry, undertakes Health Technology Assessments for the Australian Federal Government, hosts two Cochrane Collaboration entities (Breast Cancer Review Group, Prospective Meta-analysis Methods Group) and has an extensive test evaluation research program.

Lisa’s clinical background is in perinatal medicine and she has worked in healthcare systems in Asia, Australia, UK and USA. She has Masters and Doctoral qualifications in epidemiology from Sydney Medical School, is a Senior Principal Research Fellow at the University of Sydney and has held an NHMRC Postgraduate Scholarship, a Sidney Sax Postdoctoral Fellowship, a Career Development Fellowship and currently, a Translating Research Into Practice (TRIP) Fellowship.

Prof Askie has a long standing interest in the conduct and methodology of clinical trials and systematic reviews, especially regarding increasing research transparency and reducing waste. She has been involved with the Cochrane Collaboration since 1996 as a systematic review author and trainer. Lisa is the co-convenor of the Cochrane Prospective Meta-analysis Methods Group and member of the Cochrane Methods Editorial Board. Prof Askie has published over 100 scientific papers and is a member of various academic advisory boards.



James Lynam

Dr Lynam is a Medical Oncologist specialising in the care of patients with gastro-intestinal, genitourinary and brain cancers.  He is a principal and sub investigator in numerous Phase I to III clinical trials spanning multiple tumour types.  He is also an early career researcher with a particular interest in predictive biomarkers of drug toxicity and efficacy and in integrating novel technologies into oncological care and clinical trial conduct.



Adam Stoneley

Adam is the Research Operation Manager for the Icon Group providing line management and operational oversight of the research activities undertaken at Icon Cancer Centres across Australia. Adam is a firm advocate of the Group’s simple vision to deliver the best care possible to as many people as possible, as close to home as possible. Innovations such as ClinTrial Refer and the uptake of the Tele-Trials initiative further enable the awareness of clinical research opportunities to a wider community and the referral and potential accrual of patients to clinical trials across Australia.